Sort   by:  
 Page size 
UnknownPET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Not available
S-EPMC4027995 | biostudies-literature
UnknownEffect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Not available
S-EPMC6625826 | biostudies-literature
UnknownFlorbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
Not available
S-EPMC4195975 | biostudies-literature
UnknownBamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Not available
S-EPMC8314785 | biostudies-literature
UnknownEffect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Not available
S-EPMC8176388 | biostudies-literature
UnknownSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Not available
S-EPMC7646625 | biostudies-literature
UnknownDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Not available
S-EPMC10352931 | biostudies-literature
Sort   by:  
 Page size